The RENAL LIFECYCLE Trial: A RCT to Assess the Effect of Dapagliflozin on Renal and Cardiovascular Outcomes in Patients With Severe CKD

NCT05374291 · clinicaltrials.gov ↗

PHASE3

Phase

ENROLLING_BY_INVITATION

Status

1750

Enrollment

OTHER

Sponsor class

Conditions

Kidney Disease, Chronic
Renal Transplant Failure
Heart Failure
Kidney Failure
Death

Interventions

DRUG: Dapagliflozin 10 mg/day (oral)
DRUG: Placebo

Sponsor

University Medical Center Groningen

Collaborators

[object Object]
[object Object]